Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011849 (
diabetes
)
277,896
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In view of the observations that (1) plasma histamine concentrations are significantly higher in diabetic patients and diabetic rats than those in controls, and (2) tissue concentrations of histamine are elevated in rats with experimental
diabetes
, we have investigated histamine synthesis, as reflected by
histidine decarboxylase
(
HDC
) activity, and histamine catabolism, as reflected by histaminase activity, in various tissues of the diabetic rat. Rats with streptozotocin-induced
diabetes mellitus
(DM) showed an increase in histamine synthesis in various tissues; this was most marked in the aorta and to a lesser, but significant, extent in the kidneys, lungs, and heart, but not in the brain, stomach, or skin. Tissue content of histamine was significantly increased in all tissues except the stomach and skin. We conclude that tissue histamine synthesis is significantly increased in diabetic animals and that this increase is most marked in the aorta. The elevation in
HDC
activity in these tissues probably accounts for the increase in tissue and plasma concentrations of histamine in diabetic animals, since there is no change in histamine catabolism. This increase in histamine synthesis and release may contribute to the pathogenesis of endothelial damage in diabetic microangiopathy and macroangiopathy.
...
PMID:Histamine synthesis and catabolism in various tissues in diabetic rats. 237 78
Histamine (HA) metabolism in the brain of mice with streptozotocin (STZ)-induced
diabetes
was examined. The levels of tele-methylhistamine (t-MH), a major metabolite of brain HA, significantly increased 3 and 4 weeks after STZ injection. However, the HA turnover rates in the diabetic mice, determined from the accumulation of t-MH after the administration of pargyline, were not different from the control values when the animals were allowed free access to food. When the mice were starved for 15 h 4 weeks after STZ treatment, the brain levels of L-histidine decreased significantly, whereas HA turnover increased significantly. Such changes were not observed in starved control mice.
Histidine decarboxylase
or HA N-methyltransferase activity did not change after starvation in either diabetic or control mice. These results show that the histaminergic (HAergic) activity in the brains of diabetic mice remains within normal range as long as the animals are allowed free access to food. However, they also indicate that a marked enhancement of HAergic activity accompanied by a decrease in the brain L-histidine level occurs in starved diabetic mice.
...
PMID:Changes in histamine metabolism in the brains of mice with streptozotocin-induced diabetes. 270 9
Previous work has shown that plasma and tissue concentrations of histamine are elevated in rats with experimental
diabetes mellitus
and that leucocytes and platelets from patients with peripheral vascular disease have a higher histamine content than those from controls. In the present study, we have measured: (a) plasma histamine concentrations; (b) leucocyte and platelet
histidine decarboxylase
(the enzyme responsible for the biosynthesis of histamine) in patients with
diabetes mellitus
(Types I and II) and peripheral vascular disease; and (c) platelet and leucocyte histamine content. Plasma histamine concentration was significantly higher in patients with
diabetes
and peripheral vascular disease respectively than that in age-matched controls. Leucocyte
histidine decarboxylase
activity in diabetic and peripheral vascular disease patients was similar to that in controls, while platelets had no
histidine decarboxylase
activity. The leucocyte and platelet content of histamine were greater in patients with peripheral vascular disease than those in controls, but they were not altered in diabetic patients. There was no correlation between plasma histamine concentration, leucocyte and platelet histamine content, and
histidine decarboxylase
activity. We conclude that plasma histamine is elevated in diabetics and in patients with peripheral vascular disease and that platelet and leucocyte histamine content is increased in the latter. This increase in platelet and leucocyte histamine content is not due to an increase in
histidine decarboxylase
activity of these cells. The increase in plasma and cellular histamine content may contribute to the pathogenesis of increased endothelial permeability in
diabetes
and to the pathogenesis of intimal damage in atherosclerosis.
...
PMID:Plasma histamine concentrations are elevated in patients with diabetes mellitus and peripheral vascular disease. 291 44
We examined retinal de novo histamine synthesis mediated by retinal
histidine decarboxylase
in normal and streptozotocin-diabetic male, Sprague Dawley rats that were diabetic for 21 days. We also examined effects of insulin and alpha-hydrazinohistidine (alpha HH) treatments on retinal histamine synthesis in this diabetic model. alpha HH is a specific inhibitor of
histidine decarboxylase
. Results indicate that the retina contains an active
histidine decarboxylase
enzyme system, and that in streptozotocin
diabetes
retinal histamine synthesis is increased 197%. Both insulin and alpha HH independently reverse and normalize retinal histamine synthesis. These data thus indicate that the retinal inducible histamine pool is increased in experimental
diabetes
, and that insulin is an important modulator of retinal histamine metabolism. This newly described retinal metabolic alteration may be one factor responsible for increased retinal vascular permeability in diabetic retinopathy.
...
PMID:Retinal histamine synthesis is increased in experimental diabetes. 297 Oct 25
Plasma histamine concentrations were measured in rats made diabetic via jugular vein injection of streptozotocin and held 4 weeks following
diabetes
diagnosis. At least 15 diabetic animals received insulin (6-8 U/day) or alpha-hydrazinohistidine (alpha-HH) for the last week of the holding period. alpha-HH is a specific inhibitor of
histidine decarboxylase
(HD), the principle histamine-forming enzyme in mammals. Plasma histamine concentrations, expressed as means and mean standard errors (ng/ml) were as follows: control, 25.5 +/- 2.4; diabetic, 47.1 +/- 5.2; diabetic-insulin, 34.6 +/- 2.9; diabetic-alpha-HH, 28.1 +/- 2.1. These data indicate that in experimental
diabetes
there is an expansion of the nascent, or inducible histamine pool, an increase which is reflected by increased circulating plasma histamine. This may be one component mediating altered microvessel as well as large vessel permeability characteristics, an underlying component of both diabetic microangiopathy and macroangiopathy.
...
PMID:Changes in plasma histamine concentration in the streptozotocin-diabetic rat. 315 96
We examined the interrelationship between inhibition of aortic histamine synthesis through inhibition of aortic
histidine decarboxylase
and intra-aortic albumin accumulation in rats made diabetic by a jugular vein injection of 60 mg/kg of streptozotocin under ether anesthesia. Animals were held for 4 weeks following overt manifestation of
diabetes
. At the end of 3 weeks, at least six animals in each of the diabetic and non-diabetic groups received intra-peritoneal injections of alpha-hydrazinohistidine (25 mg/kg at 12 h) for the last 7 days. Aortic albumin accumulation was measured by quantification of aortic uptake of fluorescein isothiocyanate conjugated to rat serum albumin injected in the jugular vein 1 h before sacrifice. The aortic albumin mass transfer and flux rates of the diabetic group were more than 300% higher than that of the control group; alpha-hydrazinohistidine treated diabetic rats had aortic albumin mass transfer rates equivalent to control values. The aortic albumin content was nearly tenfold higher in untreated diabetic rats, but again treatment with alpha-hydrazinohistidine returned this to control values. These data offer strong support to the premise that accelerated aortic histamine synthesis, which occurs in experimental
diabetes
, is an important mediator of increased aortic macromolecule uptake, and as such, may be one component of the multitude of factors responsible for increased susceptibility of atherosclerosis among individuals having
diabetes mellitus
.
...
PMID:Inhibition of aortic histamine synthesis by alpha-hydrazinohistidine inhibits increased aortic albumin accumulation in experimental diabetes in the rat. 401 54
We studied rat aortic endothelial and smooth muscle cell de novo histamine synthesis mediated by
histidine decarboxylase
(HD) and the effects of its inhibition by alpha-hydrazinohistidine on the intracellular histamine content and intraaortic albumin accumulation in streptozotocin-induced
diabetes
.
Diabetes
was induced by a single jugular vein injection of streptozotocin (60 mg/kg, pH 4.5, ether anesthesia), with animals held 4 weeks following the overt manifestation of
diabetes
. Additional diabetic and nondiabetic rats received alpha-hydrazinohistidine (25 mg/kg, i.p. every 12 hours) during the last week; this had no effect on the severity of
diabetes
in any animal receiving streptozotocin. Data indicate that the aortic endothelial (EC) HD activity was increased more than 130% in the untreated diabetic group but was similar to control values in the diabetic group receiving alpha-hydrazinohistidine; similarily, the EC histamine content from diabetic aortas increased 127% over control values, but in EC from diabetic animals receiving alpha-hydrazinohistidine it was comparable to control values. Similar trends were observed for the subjacent aortic smooth muscle. In untreated diabetic animals the aortic 125I-albumin mass transfer rate was increased 60% over control values, while in diabetic animals receiving alpha-hydrazinohistidine the 125I-albumin mass transfer rate was essentially identical to controls. These data indicate that in streptozotocin
diabetes
there is an expansion of the inducible aortic histamine pool, and that this expansion is intimately related to the increased aortic albumin accumulation.
...
PMID:Aortic endothelial and smooth muscle histamine metabolism. Relationship to aortic 125I-albumin accumulation in experimental diabetes. 665 15
We studied histamine metabolism, i.e.,
histidine decarboxylase
(HD)-mediated synthesis and histaminase-mediated catabolism, in relation to intracellular histamine content in both aortic endothelial and subjacent smooth muscle cells of control and diabetic rats.
Diabetes
was induced by a single jugular vein injection of streptozotocin (55 mg/kg in acidified saline, pH 4.5), and animals were held for either 2 or 4 weeks following overt manifestation of
diabetes
. An additional 4-week diabetic group received insulin (Iletin NPH, 10 U per 24 hour) during the last week. With respect to control values, the histamine content of aortic endothelial cells increased 138%, HD activity increased 250%, and histaminase activity decreased 50% over the 4-week period. In subjacent smooth muscle cells, the histamine content increased in excess of 150%, HD activity increased more than 300%, and histaminase activity decreased in excess of 30%. Insulin treatment for the last week resulted in complete reversal of all these changes. These results support the concept that a large vessel response similar to the microcirculatory prolonged phase of inflammation occurs in experimental
diabetes
, a change similar to that occurring in experimental atherosclerosis. They also indicate that both synthetic and catabolic changes occur in histamine metabolism under these conditions, changes that alter arterial wall histamine pools, and suggest that insulin administration under conditions of experimental
diabetes
may modulate aortic histamine metabolism and the resultant intraaortic histamine pools.
...
PMID:Aortic endothelial and smooth muscle histamine metabolism in experimental diabetes. 680 15
Leptin, an ob gene product, has been shown to suppress food intake by regulating hypothalamic neuromodulators. The present study was designed to examine the involvement of brain histamine in leptin-induced feeding suppression. A bolus infusion of 1.0 microg leptin into the rat third cerebroventricle (i3vt) elevated the turnover rate of hypothalamic neuronal histamine (P < 0.05) as assessed by pargyline-induced accumulation of tele-methylhistamine (t-MH), a major metabolite of histamine. No remarkable change in the mRNA expression of
histidine decarboxylase
(
HDC
), a histamine-synthesizing enzyme, was observed in the hypothalamus after i3vt infusion of leptin. These results indicate that leptin increases histamine turnover by affecting the posttranscriptional process of
HDC
formation or histamine release per se. As expected, concomitant suppression in 24-h cumulative food intake was also observed after infusion of leptin. Systemic depletion of brain histamine levels by pretreatment with an intraperitoneal injection of 224 micromol/kg alpha-fluoromethylhistidine (FMH), a suicide inhibitor of
HDC
, attenuated the leptin-induced feeding suppression by 50.7% (P < 0.05). This attenuation of feeding suppression was mimicked by the i3vt infusion of 2.24 micromol/kg FMH before leptin treatment (P < 0.05). In addition, concentrations of hypothalamic histamine and t-MH were lowered in diabetic (db/db) mice, which are known to be deficient in leptin receptors (P < 0.05 vs. lean littermates for each amine), although the amine levels were higher in diet-induced obese rats (P < 0.05 for each amine). Leptin-deficient obese mice (ob/ob) showed lower histamine turnover (P < 0.05 vs. lean littermates), which recovered after leptin infusion. Thus, a growing body of results points to an important role for the hypothalamic histamine neurons in the central regulation of feeding behavior controlled by leptin.
Diabetes
1999 Dec
PMID:Hypothalamic neuronal histamine as a target of leptin in feeding behavior. 1058 Apr 15
Histamine is a classical, but still interesting inflammatory mediator. Many people have long believed that histamine is derived from mast cells or basophils alone. However, the histamine-forming enzyme,
histidine decarboxylase
(
HDC
), is induced in a variety of tissues in response (i) to gram-positive and gram-negative bacterial components (lipopolysaccharides, peptidoglycan, and enterotoxin A) and (ii) to various cytokines (IL-1, IL-3, IL-12, IL-18, TNF, G-CSF, and GM-CSF).
HDC
is induced even in mast-cell-deficient mice. The histamine newly formed via the induction of
HDC
is released immediately and may be involved in a variety of immune responses. Reviewing our work and that of Schayer and Kahlson, the pioneers in this field, lead us to the conclusion that nowadays we need to understand that histamine can be produced via the induction of
HDC
by a mechanism coupled with the cytokine network. We call this histamine "neohistamine", to distinguish it from the classical histamine derived from mast cells or basophils. Neohistamine is involved in physiological reactions, inflammation, immune responses and a variety of diseases such as periodontitis, muscle fatigue (or temporomandibular disorders), stress- or drug-induced gastric ulcers, rheumatoid arthritis, complications in
diabetes
, hepatitis, allograft rejection, allergic reactions, tumor growth, and inflammatory side effects of aminobisphosphonates.
...
PMID:[Induction of histidine decarboxylase in inflammation and immune responses]. 1149 27
1
2
Next >>